Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: The ASSET randomised controlled trial

Annals of the Rheumatic Diseases

Volumn 72, Issue 8, 2013, Pages 1287-1294

  Conaghan, Philip G ^a   Durez, Patrick ^b   Alten, Rieke E ^c   Burmester, Gerd Rüdiger ^d   Tak, Paul P ^e,f   Klareskog, Lars ^g   Catrina, Anca Irinel ^g   DiCarlo, Julie ^h   Gaillez, Corine ⁱ   Le Bars, Manuela ⁱ   Zhou, Xianhuang ⁱ   Peterfy, Charles ^h  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c Schlosspark Klinik   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f GlaxoSmithKine   (United Kingdom)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h Spire Sciences LCC   (United States)

ⁱ BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; C REACTIVE PROTEIN; CORTICOSTEROID; METHOTREXATE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ACTIVITY SCORE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; INFECTION; MALE; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SYNOVITIS; TREATMENT OUTCOME;

DISEASE ACTIVITY; MAGNETIC RESONANCE IMAGING; RHEUMATOID ARTHRITIS; SYNOVITIS; T CELLS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOCONJUGATES; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; METHOTREXATE; MIDDLE AGED; OSTEITIS; SYNOVITIS; TREATMENT OUTCOME; WRIST JOINT;

EID: 84880206715     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201611     Document Type: Article

References (34)

1. McGonagle D, Conaghan PG, O'Connor P, et al. The relationship between synovitis and bone changes in early untreated rheumatoid arthritis: a controlled magnetic resonance imaging study. Arthritis Rheum 1999;42:1706-11. (Pubitemid 30263640)
2. Brown AK, Wakefield RJ, Conaghan PG, et al. New approaches to imaging early inflammatory arthritis. Clin Exp Rheumatol 2004;22(5 Suppl 35):S18-25. (Pubitemid 39328352)
3. Conaghan PG, Emery P, Ostergaard M, et al. Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial. Ann Rheum Dis 2011;70:1968-74.
4. Ostergaard M, Emery P, Conaghan PG, et al. Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients. Arthritis Rheum 2011;63:3712-22.
5. Freeston JE, Bird P, Conaghan PG. The role of MRI in rheumatoid arthritis: research and clinical issues. Curr Opin Rheumatol 2009;21:95-101.
6. Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008;58:1299-309. (Pubitemid 351705919)
7. Durez P, Malghem J, Nzeusseu Toukap A, et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum 2007;56:3919-27. (Pubitemid 350262784)
8. Genovese MC, Kavanaugh A, Weinblatt ME, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 2011;63:337-45.
9. Peterfy C, Emery P, Tak PP, et al. Rituximab (RTX) plus methotrexate (MTX) prevents bone erosion and joint-space narrowing ( JSN) and reduces synovitis, osteitis as shown on MRI: Results from a randomised, placebo-controlled trial in patients (PTS) with rheumatoid arthritis (RA-score). Ann Rheum Dis 2011;70(3 (Suppl.)):152.
10. Peterfy C, Haraoui B, Durez P, et al. Decreased incidence of synovitis, osteitis, and erosion in early RA patients treated with adalimumab plus methotrexate compared to those with methotrexate alone: high-field MRI analysis from OPTIMA (Abstract 123). Arthritis Rheum 2010;62:S51.
11. Peterfy CG, Countryman P, Gabriele A, et al. Magnetic resonance imaging in rheumatoid arthritis clinical trials: emerging patterns based on recent experience. J Rheumatol 2011;38:2023-30.
12. Bathon J, Robles M, Ximenes AC, et al. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis 2011;70:1949-56.
13. Genant HK, Peterfy C, Westhovens R, et al. Abatacept increases the proportion of patients who remain free from structural damage progression through 5 Years in methotrexate inadequate responders with RA. Ann Rheum Dis 2009;68(Suppl 3):440.
14. Genant HK, Peterfy CG, Westhovens R, et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 2008;67:1084-9.
15. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-76. (Pubitemid 46768126)
16. Kremer JM, Russell AS, Emery P, et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis 2011;70:1826-30.
17. Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009;68:1870-7.
18. Ostergaard M, Peterfy C, Conaghan P, et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol 2003;30:1385-6. (Pubitemid 36666373)
19. Bruynesteyn K, Boers M, Kostense P, et al. Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis 2005;64:179-82. (Pubitemid 40193607)
20. Buch MH, Boyle DL, Rosengren S, et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 2009;68:1220-7.
21. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:27-35. (Pubitemid 40129229)
22. Haavardsholm EA, Ostergaard M, Ejbjerg BJ, et al. Reliability and sensitivity to change of the OMERACT rheumatoid arthritis magnetic resonance imaging score in a multireader, longitudinal setting. Arthritis Rheum 2005;52:3860-7. (Pubitemid 41798224)
23. Emery P, Durez P, Dougados M, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 2010;69:510-16.
24. Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011;63:939-48.
25. Palosaari K, Vuotila J, Takalo R, et al. Bone oedema predicts erosive progression on wrist MRI in early RA-a 2-yr observational MRI and NC scintigraphy study. Rheumatology (Oxford) 2006;45:1542-8. (Pubitemid 44822018)
26. Conaghan PG, O'Connor P, McGonagle D, et al. Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis Rheum 2003;48:64-71. (Pubitemid 36091649)
27. Boyesen P, Haavardsholm EA, Ostergaard M, et al. MRI in early rheumatoid arthritis: synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression. Ann Rheum Dis 2011;70:428-33.
28. Reece RJ, Kraan MC, Radjenovic A, et al. Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. Arthritis Rheum 2002;46:366-72. (Pubitemid 34136573)
29. Troum O, Peterfy C, Kaine J, et al. Tocilizumab redcues synovitis within 2 weeks and pre-erosive osteitis within 12 weeks in patients with RA: results from a multi-site low-field MRI study (Abstract OP0135). Ann Rheum Dis 2010;69 (Suppl 3):98.
30. Peterfy C, Emery P, Tak PP, et al. (OP0246) Rituximab (RTX) plus methotrexate (MTX) prevents bone erosion and joint-space narrowing ( JSN) and reduces synovitis, osteitis as shown on MRI: Results from a randomised, placebo-controlled trial in patients (PTS) with rheumatoid arthritis (RA-score). Ann Rheum Dis 2011;70(Suppl 3):152.
31. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-103.
32. Durez P, Alten R, Tak PP, et al. The relationship between MRI outcomes and clinical efficacy in abatacept-treated patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX). Ann Rheum Dis 2011;70(Suppl 3): SAT0284.
33. Hochberg M, Westhovens R, Aranda R, et al. Long-term safety profile of abatacept (Orencia) from the rheumatoid arthritis clinical trial program; integrated analysis of data from 12, 132 patient-years of exposure. Arthritis & Rheumatism 2010;62(10 Suppl):S164-5.
34. Alten R, Kaine J, Keystone E, et al. Safety of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis (RA): Integrated Analysis of Five Clinical Trials up to 4.5 Years. Presented at EULAR, London, 25-28th May 2011. Poster SAT0292 2011.